NADAC acquisition cost data for APLENZIN ER 522 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00187581230 | $166.52 | 2022-01-01 | Rx |
| 00187581230 | $166.52 | 2022-01-01 | Rx |
| 00187581230 | $166.52 | 2022-01-01 | Rx |
| 00187581230 | $166.52 | 2022-01-01 | Rx |
| 00187581230 | $166.52 | 2022-01-01 | Rx |
| 00187581230 | $166.52 | 2022-01-01 | Rx |
| 00187581230 | $166.52 | 2022-01-01 | Rx |
| 00187581230 | $166.52 | 2022-01-01 | Rx |
| 00187581230 | $166.52 | 2022-01-01 | Rx |
| 00187581230 | $166.52 | 2022-01-01 | Rx |
Generic: Bupropion HBr | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $10.8M | 2,894 | 504 | $101.01 |
| 2020 | $14.1M | 3,409 | 527 | $108.18 |
| 2021 | $15.3M | 3,477 | 575 | $115.32 |
| 2022 | $18.3M | 3,997 | 678 | $121.62 |
| 2023 | $20.3M | 4,330 | 741 | $124.96 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $2.4M | 513 | 85 |
| California | $2.1M | 487 | 89 |
| Florida | $1.6M | 444 | 81 |
| Texas | $1.3M | 206 | 46 |
| Ohio | $1.2M | 278 | 39 |
| Georgia | $1.1M | 215 | 37 |
| New Jersey | $1.1M | 272 | 39 |
| North Carolina | $893.8K | 206 | 36 |
| Alabama | $713.1K | 163 | 30 |
| Connecticut | $701.2K | 109 | 22 |
| Tennessee | $635.3K | 100 | 15 |
| Massachusetts | $624.1K | 67 | 13 |
| Kentucky | $612.7K | 130 | 25 |
| Arizona | $498.9K | 84 | 15 |
| Pennsylvania | $483.2K | 103 | 18 |
| Illinois | $459.2K | 68 | 13 |
| South Carolina | $441.4K | 89 | 20 |
| Virginia | $337.7K | 68 | 12 |
| Wisconsin | $329.5K | 62 | N/A |
| Louisiana | $325.2K | 71 | 13 |
| Michigan | $318.7K | 73 | 15 |
| Indiana | $310.6K | 67 | N/A |
| Kansas | $309.0K | 68 | 11 |
| Delaware | $203.3K | 64 | 15 |
| Missouri | $167.6K | 35 | N/A |
| Maryland | $131.7K | 44 | N/A |
| Colorado | $128.8K | 35 | N/A |
| Minnesota | $125.6K | 16 | N/A |
| Oregon | $110.3K | 54 | N/A |
| Washington | $86.2K | 41 | N/A |
| Iowa | $77.8K | 13 | N/A |
| Nebraska | $77.4K | 29 | N/A |
| Mississippi | $76.0K | 15 | N/A |
| South Dakota | $32.0K | 12 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.